A 30-year-old woman presented to hospital 8 days after vaccination against SARS-CoV-2 with the second dose of the Moderna mRNA vaccine. One day postvaccination, she noted flu-like symptoms, including chills and nausea. Three days postvaccination, she developed neuromuscular symptoms, including progressive bilateral upper and lower limb myalgia and weakness. At 7 days, she noticed cola-coloured urine. She had been vaccinated with the first dose of Moderna mRNA SARS-CoV-2 vaccine 6 months earlier, and had not displayed these symptoms or any complications.

The patient had no known history of SARS-CoV-2 infection. Her medical history included 5 previous episodes of rhabdomyolysis since age 10, usually triggered by viral infections. She had a previously identified mutation in the ryanodine receptor 1 (RYR1) gene at the canonical splice site (c.12624+1_124+2insT), which increased her risk for development of malignant hyperthermia and rhabdomyolysis. She had not had rhabdomyolysis following previous vaccinations. Additional medical history included schizoaffective disorder, latent tuberculosis 5 years ago, polycystic ovarian syndrome, iron deficiency anemia and obstructive sleep apnea. Her medications were atorvastatin, clozapine, lithium, flupentixol, ferrous gluconate and vitamin D. Her anti-psychotic medications had been prescribed since 2015. She had not had any recent dose adjustments or additions to her medication regimen. She reported not taking any herbal or over-the-counter substances.

The patient had no focal neurologic deficits, rashes or arthralgias. She had not had recent strenuous exercise, trauma or prolonged heat exposure, and she reported no alcohol or recreational drug consumption. At presentation, her blood pressure was 143/88 mm Hg, her heart rate was 118 beat/min, her respiratory rate was 16 breaths/min, her oxygen saturation was 98% on room air, and she had a temperature of 36.3°C. Cardiovascular, respiratory, abdominal and dermatologic examinations were unremarkable. Neurological findings included symmetric muscle power in the proximal and distal upper and lower limbs (4/5 using the Medical Research Council’s scale for muscle strength), with an otherwise normal musculoskeletal examination. No altered mental status, diaphoresis, rigidity or hyperreflexia were evident.

Our differential diagnosis included rhabdomyolysis, malignant hyperthermia, serotonin syndrome and neuroleptic malignant syndrome, as well as viral infection. Although our patient was taking antipsychotic medication, neuroleptic malignant syndrome and serotonin syndrome were unlikely given that she had no autonomic instability, clonus, rigidity, hyporeflexia, hyperthermia or altered mental status.

The results of investigations are in Table 1. Initial blood tests at 8 days postvaccination showed a creatine kinase (CK) of 203 088 (normal 30–150) U/L, with no evidence of renal impairment, and normal electrolyte levels. Urinalysis revealed blood (3+), with no red blood cells. A magnetic resonance imaging scan of her thighs showed diffusely heterogeneous, symmetric, intramuscular and intermuscular high T2 and short tau inversion recovery signals involving the thigh musculature (Figure 1). We diagnosed rhabdomyolysis, possibly in association with vaccination, but we could not definitively rule out viral-induced rhabdomyolysis; we did not perform nasopharyngeal polymerase chain reaction testing for SARS-CoV-2.

Key points

- We report a case of severe rhabdomyolysis in a patient with a ryanodine receptor 1 (RYR1) gene mutation who presented 8 days after receiving a second dose of Moderna mRNA vaccine against SARS-CoV-2.
- Onset of rhabdomyolysis after SARS-CoV-2 vaccination is variable, ranging from less than 24 hours to 7 days after the administration of the vaccine, with symptoms that include limb myalgia, weakness and difficulty ambulating.
- In severe cases of rhabdomyolysis, clinicians should consider neuroleptic malignant syndrome, malignant hyperthermia and serotonin syndrome in their differential diagnosis.
- The mainstay of treatment for rhabdomyolysis is intravenous fluid resuscitation.
- For patients with an underlying medical condition that may make them more susceptible to rhabdomyolysis (e.g., muscle dystrophy, metabolic or mitochondrial myopathy, RYR1-related disease), clinicians should counsel on signs of rhabdomyolysis and should check the patient’s creatinine kinase level within 1 week of vaccination.

Our differential diagnosis included rhabdomyolysis, malignant hyperthermia, serotonin syndrome and neuroleptic malignant syndrome, as well as viral infection. Although our patient was taking antipsychotic medication, neuroleptic malignant syndrome and serotonin syndrome were unlikely given that she had no autonomic instability, clonus, rigidity, hyporeflexia, hyperthermia or altered mental status.

The results of investigations are in Table 1. Initial blood tests at 8 days postvaccination showed a creatine kinase (CK) of 203 088 (normal 30–150) U/L, with no evidence of renal impairment, and normal electrolyte levels. Urinalysis revealed blood (3+), with no red blood cells. A magnetic resonance imaging scan of her thighs showed diffusely heterogeneous, symmetric, intramuscular and intermuscular high T2 and short tau inversion recovery signals involving the thigh musculature (Figure 1). We diagnosed rhabdomyolysis, possibly in association with vaccination, but we could not definitively rule out viral-induced rhabdomyolysis; we did not perform nasopharyngeal polymerase chain reaction testing for SARS-CoV-2.
We treated the patient’s rhabdomyolysis with intravenous fluid resuscitation. Given her RYR1 mutation and the potential for malignant hyperthermia, despite absence of neurologic sequelae at 9 days postvaccination, we also started oral dantrolene (25 mg, 3 times a day). Her myalgia and weakness continued to worsen, with a peak CK of 586 647 U/L at 11 days postvaccination. Given the patient’s 2-year history of statin exposure, we consulted a rheumatologist to exclude inflammatory myopathy. We had stopped atorvastatin at presentation. Testing for 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase antibody and a myositis panel were negative. After 7 days of treatment without immunosuppression, she improved clinically, providing evidence against immune-mediated myopathy, and her CK normalized by day 10 of admission (18 days postvaccination).

**Discussion**

Rhabdomyolysis is a syndrome characterized by muscle necrosis and release of intracellular muscle constituents into peripheral circulation. About 25 000 cases are reported each year in the United States. The severity of illness ranges from asymptomatic elevation in muscle enzymes to life-threatening complications.

---

### Table 1: Laboratory investigations during hospital admission*

| Investigation | 8 days postvaccine | 11 days postvaccine | 20 days postvaccine | Reference range |
|---------------|--------------------|---------------------|---------------------|-----------------|
| Creatinine, μmol/L | 69 | 67 | 66 | 58–110 |
| Urea, mmol/L | 1.8 | – | – | 2.7–6.7 |
| Sodium, mmol/L | 143 | 142 | 140 | 135–145 |
| Potassium, mmol/L | 3.3 | 5.3 | 3.7 | 3.5–5 |
| Chloride, mmol/L | 108 | 110 | 105 | 95–110 |
| Magnesium, mmol/L | 0.89 | 0.89 | 0.81 | 0.70–1.10 |
| Phosphate, mmol/L | 1.72 | 1.78 | 1.85 | 0.90–1.52 |
| Calcium, mmol/L | 2.12 | 2.33 | 2.30 | 2.10–2.60 |
| Albumin, g/L | 36 | 37 | 36 | 35–50 |
| Creatine kinase, U/L | 203 088 | 586 647 | 5772 | 30–150 |
| Hemoglobin, g/L | 129 | 126 | 99 | 115–165 |
| Mean corpuscular volume, fl | 86.1 | 90.1 | 94.1 | 82–99 |
| Platelets, x 10^9/L | 236 | 282 | 266 | 150–400 |
| Leukocytes, x 10^9/L | 9.6 | 10.8 | 6.7 | 4–11 |
| Lymphocytes, x 10^9/L | 1.9 | 2.5 | 2.3 | 1.5–4 |
| Neutrophils, x 10^9/L | 7.3 | 8.0 | 4.0 | 2–7.5 |
| Venous blood gas | | | | |
| pH | 7.37 | 7.42 | 7.42 | 7.32–7.42 |
| pCO₂, mm Hg | 44 | 47 | 46 | 38–50 |
| Bicarbonate, mmol/L | 25 | 31 | 30 | 24–30 |
| Liver enzymes | | | | |
| Aspartate aminotransferase, U/L | 673 | 1376 | 109 | 18–34 |
| Alanine aminotransferase, U/L | 68 | 191 | 94 | 0–34 |
| γ-Glutamyl transferase, U/L | 27 | 42 | – | < 37 |
| Alkaline phosphatase, U/L | 96 | 96 | – | 38–126 |
| Total bilirubin, μmol/L | 8 | 11 | – | < 21 |

**Note:** ANA = antinuclear antibody, anti = antibody, ANCA = antineutrophil cytoplasmic antibody, AU = arbitrary units, HMG-CoA = 3-hydroxy-3-methylglutaryl–coenzyme A, MDA5 = melanoma differentiation-associated gene 5, pCO₂ = partial pressure of carbon dioxide, SRP = signal recognition particle, TIF1 = transcription intermediary factor 1. Investigations for autoimmune markers (ANA screen, anti-Mi-2-α, anti-Mi-2-β, anti-TIF1-γ, anti-MDA5, anti-β2-microglobulin, anti-SAE1, anti-Ku, anti-PM/Scl-100, anti-PM/Scl-75, anti-Jo1, anti-SRP, anti-PL-7, anti-PL-12, anti-OJ, anti-Ro-52, anti-HMG-CoA reductase) were all negative, aside from P-ANCA and C-ANCA (both < 0.2 AU/mL at day 11 and < 1.0 AU/mL at day 20).
involving acute kidney injury, disseminated intravascular coagulation, compartment syndrome and electrolyte abnormalities. Acute kidney injury is one of the most serious and common complications of rhabdomyolysis, with a mortality rate of about 10%.  

**Diagnosis**

A thorough history and examination, in combination with CK measurements, are integral to diagnosing rhabdomyolysis. The characteristic triad of rhabdomyolysis symptoms is myalgia, weakness and dark urine; however, this occurs in only 10% of patients. Rhabdomyolysis has numerous triggers, including exercise, medications (e.g., lithium) and infection (Box 1). Differentiating between syndromes that include rhabdomyolysis as a complication — including neuroleptic malignant syndrome, malignant hyperthermia and serotonin syndrome — can help direct onward management (Table 2).

With rhabdomyolysis, serum CK levels at presentation tend to be at least 5 times the upper limit of normal, often more than 5000 IU/L, although there is no absolute cut-off. An MRI scan can be helpful for identifying the underlying cause, as symmetric muscle edema implies inflammatory and drug-related myopathies, and asymmetric edema suggests trauma. A muscle biopsy can confirm the diagnosis, but is not usually necessary.

**SARS-CoV-2 vaccination and rhabdomyolysis**

Rhabdomyolysis has been described as a complication of viral infection, including SARS-CoV-2. One retrospective cohort study of 140 patients admitted to hospital with COVID-19 showed a 16.9% incidence of rhabdomyolysis; patients who developed rhabdomyolysis were significantly more likely to die than those who did not (47.1% v. 26.4%).

As with other vaccinations, rhabdomyolysis may be associated with vaccination against SARS-CoV-2. As of Jan. 14, 2022, according to the Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System, 214 cases of rhabdomyolysis have been reported after SARS-CoV-2 vaccination. Six case reports have been published. In the first report, an 80-year-old man with diabetes developed myalgia and weakness 2 days post-vaccination for SARS-CoV-2 with his second dose of Moderna. His CK peaked at 6546 U/L and was responsive to intravenous fluids. Similarly, a 21-year-old man with asthma presented with lower back pain and swelling for 1 day, with a CK of 22 000 U/L, after his first Pfizer/BioNTech vaccine. Another report described a 28-year-old woman with no medical history who presented with myalgia and weakness and a CK of 17 969 U/L, 5 days after her first Moderna vaccine. A 19-year-old man received the Johnson & Johnson vaccine and was noted to have myalgia and immobility 1 day after vaccination. He had a CK of 15 628 U/L and a negative myositis antibody panel. An 85-year-old woman with a recent history of cerebrovascular accident presented with...
weakness, muscle cramps, hematuria, acute kidney injury and a CK of more than 14 000 U/L 2 days after her second dose of Moderna vaccine. Despite fluid resuscitation, she deteriorated and ultimately died of cardiac arrest, complicated in part by acute heart failure, infection and renal failure. Lastly, a 34-year-old man with carnitine palmitoyltransferase II deficiency (a disorder of long-chain fatty acid oxidation resulting in myopathy) developed rhabdomyolysis (CK 250 000 U/L) within 24 hours of receiving the AstraZeneca vaccine.11

**RYR1 gene and rhabdomyolysis**

Our patient had a pathogenic mutation of the *RYR1* gene. This gene encodes the ryanodine receptor located in the sarcoplasmic reticulum membrane of skeletal muscle cells.12 Dysfunction in *RYR1* can lead to impairment in muscle contraction, leading to weakness, and patients may have a lower threshold for rhabdomyolysis. As our patient had previously documented events of rhabdomyolysis secondary to viral illness, we believe she may have been sensitive to systemic inflammatory responses. Vaccines can induce the release of myotoxic cytokines, including tumour necrosis factor, resulting in skeletal muscle breakdown and subsequent rhabdomyolysis.9 In our patient, we speculate that the second dose of SARS-CoV-2 vaccine may have generated a more robust immune response, with myotoxic cytokine release leading to rhabdomyolysis, compared with the first dose. Although causality cannot be proven, the temporal relation between mRNA SARS-CoV-2 vaccination and development of myalgia, severe CK elevation and diffuse muscle edema on imaging supports a possible association, with a score of 2 on the Naranjo Adverse Drug Reaction Probability Scale (https://www.evidencio.com/models/show/661).

Although mRNA vaccination against SARS-CoV-2 is the most likely trigger of rhabdomyolysis in our patient, she was also taking lithium and atorvastatin, which may have been confounding or contributing factors. A negative HMG-CoA reductase antibody, and improvement without immunosuppression, argues against statin-associated, immune-mediated necrotizing myopathy, but statin use has been associated with increased risk of rhabdomyolysis in individuals with *RYR1* mutations.13 Use of antipsychotics is also a known risk factor for rhabdomyolysis, particularly in patients taking multiple agents, as in our patient.14

**Clinical course**

Our patient’s neuromuscular symptoms began 3 days postvaccination, with a peak in CK 11 days postvaccination (Figure 2). The typical time course of CK is a rise within 12 hours of muscle injury, peaking within 1–3 days and declining 3–5 days after cessation of muscle injury.1 Our patient’s CK peaked later than expected, and her CK level was higher than other published cases. Whether these differences are related to a vaccine-specific rhabdomyolysis response or her underlying risk factors is unclear.

Of note, the very high CK level did not result in renal impairment. However, our patient was young, with normal renal function before the rhabdomyolysis, and at this degree of CK

| Characteristic | Neuroleptic malignant syndrome | Serotonin syndrome | Malignant hyperthermia |
|---------------|---------------------------------|--------------------|-----------------------|
| Inciting agent | Dopamine antagonist              | Serotonin agonist   | Inhaled or halogenated anesthetics |
| Onset         | Days to weeks                   | < 24 hours         | < 24 hours            |
| Course        | Resolves within 7–9 days of onset with treatment | Resolves within 24 hours of onset with treatment | Resolves within 24–48 hours of onset with treatment |
| Body temperature | Hyperthermia                    | Hyperthermia       | Hyperthermia          |
| Neuromuscular findings | Lead-pipe rigidity Bradyreflexia | Hyperreflexia Rigidity Tremor Myoclonus | Hyperreflexia Rigidity |
| Clinical features | Diaphoresis Catatonia or mutism | Diaphoresis Altered level of consciousness Increased bowel sounds | Diaphoresis Agitation Mottled skin |

![Figure 2: Change in creatine kinase levels from time of hospital admission to discharge. The peak level was at 586 647 U/L on day 4 of admission. Arrow points to the day that oral dantrolene was initiated.](image-url)
elevation, an average 30-day risk of kidney injury is 74%, with only 11% of patients requiring renal replacement therapy.15 In addition, our patient also had markedly elevated liver enzymes. It is unclear if this was related to rhabdomyolysis or to treatment with dantrolene, which has been associated with hepatotoxicity.2 It is difficult to differentiate between liver and muscle injury, and as such, the clinical context must determine whether further investigation of liver disease is warranted.

Lastly, it is unclear whether our patient’s condition improved simply from administration of intravenous fluids, which is the standard of care for rhabdomyolysis, or whether dantrolene was efficacious. Dantrolene acts as an inhibitor of the ryanodine receptor, and is typically used for malignant hyperthermia to assist with reduction of hyperthermia, CK levels and rigidity.16 We used dantrolene because of the degree of the patient’s CK elevation and her pre-existing RYR1 mutation, but clinical guidelines are lacking. Dantrolene may have attenuated muscle necrosis in our patient, but may not help in cases of vaccine-related rhabdomyolysis with different risk factors.

Conclusion
We report a case of rhabdomyolysis, possibly associated with mRNA vaccination against SARS-CoV-2, in a patient with RYR1 mutation whose other risk factors included use of a statin and multiple antipsychotic medications. To ensure prompt identification and treatment of rhabdomyolysis, clinicians should consider close monitoring after SARS-CoV-2 vaccination in patients who may have a susceptibility to rhabdomyolysis, such as those with neuromuscular conditions including muscle dystrophy, metabolic or mitochondrial myopathy, or RYR1-related disease. In these patients, we suggest clinicians obtain serum CK levels within 7 days of vaccination and advise patients to monitor for clinical features of rhabdomyolysis.

References
1. Zutt R, van der Kooi AJ, Linthorst GE, et al. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014;24:651-9.
2. LiverTox: Clinical and research information on drug-induced liver injury. In: Dantrolene. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012; updated 2017 Jan. 30. Available: https://www.ncbi.nlm.nih.gov/books/NBK546144/ (accessed 2021 Jan. 7).
3. Kateon H. Differentiating serotonin syndrome and neuroleptic malignant syndrome. Ment Health Clin 2013;3:129-33.
4. Haroun MW, Dieiev V, Kang J, et al. Rhabdomyolysis in COVID-19 patients: a retrospective observational study. Cureus 2021;13:e12552.
5. Vaccine Adverse Event Reporting System. Atlanta: Centers for Disease Control and Prevention; Silver Spring (MD): US Food and Drug Administration. Available: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html (accessed 2021 Jan. 14).
6. Mack M, Nichols L, Guerrero DM. Rhabdomyolysis secondary to COVID-19 vaccination. Cureus 2021;13:e15004.
7. Nassar M, Chung H, Dhayaparan Y, et al. COVID-19 vaccine induced rhabdomyolysis: case report with literature review. Diabetes Metab Syndr 2021;15:102170.
8. Faisnner S, Richter D, Ceylan U, et al. COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. J Neurol 2021 Aug; 25;1-2. doi: 10.1007/s00415-021-10768-3 [Epub ahead of print].
9. Gelbenegger G, Cacioppo F, Firbas C, et al. Rhabdomyolysis following Ad26.COV2.S COVID-19 vaccination. Vaccines (Basel) 2021;9:956.
10. Ajmera KM. Fatal case of rhabdomyolysis post-COVID-19 vaccine. Infect Drug Resist 2021;14:3929-35.
11. Tan A, Stepien KM, Narayana STK. Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis. QJM 2021;114:596-7.
12. Yamaguchi N. Molecular insights into calcium dependent regulation of ryanodine receptor calcium release channels. Adv Exp Med Biol 2020;1131:321-36.
13. Haseeb M, Thompson PD. The effect of statins on RyR and RyR-associated disease. J Appl Physiol 2021;131:661-71.
14. Packard K, Price P, Hanson A. Antipsychotic use and the risk of rhabdomyolysis. J Pharm Pract 2014;27:501-12.
15. Nielsen FE, Cordtz JJ, Rasmussen TB, et al. The association between rhabdomyolysis, acute kidney injury, renal replacement therapy, and mortality. Clin Epidemiol 2020;12:989-95.
16. Riazi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. Can J Anesth 2018;65:709-21.

Competing interests: Mark Tarnopolsky reports speaker fees from the American College of Sports Medicine and Haroon Yousuf reports a teaching honorarium from Touchstone Institute, outside the submitted work. No other competing interests were declared. This article has been peer reviewed.

The authors have obtained patient consent.

Affiliations: Departments of Medicine (Salter, Yousuf), Rheumatology (Jessome) and Neurology (Tarnopolsky), McMaster University, Hamilton, Ont.

Contributors: All of the authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Acknowledgement: The authors thank Dr. Faiza Khokhar for her expert guidance in rheumatology for this case.

Correspondence to: Brittany Salter, brittany.salter@medportal.ca

The section Cases presents brief case reports that convey clear, practical lessons. Preference is given to common presentations of important rare conditions, and important unusual presentations of common problems. Articles start with a case presentation (500 words maximum), and a discussion of the underlying condition follows (1000 words maximum). Visual elements (e.g., tables of the differential diagnosis, clinical features or diagnostic approach) are encouraged. Consent from patients for publication of their story is a necessity. See information for authors at www.cmaj.ca.